



Morgan Stanley ESG Conference 2020

Phil Thomson

President, Global Affairs, GSK

9 December 2020

Everyone at GSK is focused on our **three long-term** priorities, all powered by our **performance focused** culture.

Innovation


Performance

Trust

Culture




Trust aims to deliver long-term sustainable impact and reduce risk




* New environmental goals announced November 2020

Trust reflects priority ESG topics for GSK




* New environmental goals announced November 2020

Trust reflects priority ESG topics for GSK



Trust reflects priority ESG topics for GSK



We measure progress on Trust through target KPIs



Product reach

Aim to use access strategies to reach 800 million underserved people in developing countries with our products by 2025.

> **Performance:** Since we set the target in 2018 our products have reached over **192 million people**.

Healthcare access

Aim to partner to improve disease prevention, awareness and access to healthcare services for 12 million people by 2025.

> **Performance:** Since we set the target in **2018** we have reached nearly **8 million** people through these partnerships.

Engaged people

Aim to achieve and maintain a competitive employee engagement score by 2022.

> **Performance:** In 2020, Record response (85%) to our employee survey, with **engagement score of 84%**

Inclusion and diversity

Aim to have over 37% female representation in senior roles 2022.

> **Performance:** Women represent **36% of all senior management** roles (SVP/VP level)


Environment

Aim to reduce our environmental impact by one quarter by 2030

> **Performance:** Since we set our environmental targets in 2010 we have:

- Reduced carbon emissions by 34%,
- Reduced waste to landfill by 78%
- Reduced total water use by 31%

Trust: Key developments in 2020



COVID-19

- Focus on future pandemic preparedness
- Progress on solutions: 3 vaccine approaches in the clinic, 2 therapeutics in pivotal studies
- Committed to affordable pricing and global access

Global Health

- Progress in AMR R&D and launch of AMR Action Fund
- FDA approval of Tivicay PD and filed EU regulatory submission
- Positive final phase II results for candidate TB vaccine and collaboration with the Bill & Melinda Gates Medical Research Institute
- GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age

Environment

- New ambitious targets across our different businesses
- Net zero impact on climate by 2030 and net positive impact on nature by 2030

People

- New inclusion and diversity commitments

COVID-19 virus



Janneth, Investigator, Tres Cantos



Wind turbine at GSK Ware

ESG leader in key indices/benchmarks



| Agency | Type of score | Current score | Sector ranking |
|--------|--|---|--|
| | ESG score and ranking | 22.1 | Best in industry score among larger pharma market cap |
| | ESG score and ranking | 87 | 2nd in sector |
| | ESG score and ranking | AA | Top 10% of sector |
| | ESG score and ranking | 62 | 1st in the sector |
| | ESG score and ranking | B | 1st in sector |
| | ESG score and ranking | 4.5 | In the top 5 of our sector |
| | Access score and ranking | 4.01 | 1st |
| | AMR score and ranking | 86% | Lead the sector |
| | Carbon score Water score Supplier Engagement ranking | A for Water B for Carbon Supplier Engagement Leader | 7th in the sector |